Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Absolute Bioavailability and Mass Balance of NX-5948 in Healthy Males
NCT06691828Phase 1Completed
- Sponsor
- Nurix Therapeutics
- Start
- Nov 2024
- Primary completion
- Nov 2024
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bexobrutideg in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), non-Hodgkin lymphoma (NHL) and 1 more, sponsored by Nurix Therapeutics. Primary endpoints: Area Under the Curve (AUC0-inf) at 9 weeks, Half-life (T1/2) at 9 weeks and 6 more. Started Nov 2024; status: completed.
02
Drugs
bexobrutideg
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)non-Hodgkin lymphoma (NHL)Waldenstrom macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT06691828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06691828.